Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | MMP13 | P45452 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3165764 | 0.87 | MMP2 (0.53) | MMP13SMN1; SMN2MMP1MAPK1HDAC6 | |
| SCHEMBL7165785 | 0.85 | CTSK (0.58) | HDAC6 | |
| SCHEMBL27149953 | 0.85 | RAB9A (0.54) | NPC1RAB9AMAPTMMP13SMN1; SMN2 | |
| SCHEMBL17168924 | 0.84 | MAPK1 (0.64) | NPC1RAB9ASMN1; SMN2MAPK1LMNA | |
| SCHEMBL6988284 | 0.84 | HDAC6 (0.47) | NPC1RAB9AMAPTMMP13SMN1; SMN2 | |
| SCHEMBL7260803 | 0.82 | RAB9A (0.67) | NPC1RAB9AMAPTMMP13SMN1; SMN2 | |
| SCHEMBL4875670 | 0.81 | SMN1; SMN2 (0.69) | NPC1RAB9AMAPTSMN1; SMN2HSP90AA1 | |
| SCHEMBL10918829 | 0.80 | HDAC1 (0.60) | NPC1RAB9AMAPTMMP13SMN1; SMN2 | |
| SCHEMBL7145374 | 0.79 | ABCB1 (0.54) | NPC1RAB9AMAPTMMP13SMN1; SMN2 | |
| SCHEMBL10317838 | 0.79 | RAB9A (0.50) | NPC1RAB9AMAPTMMP13SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966157-B1 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS | ABBOTT LAB (US) | 2010-03-24 | — | — | EP | disclosed |
| US-7595406-B2 | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | ABBOTT LABORATORIES INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7462724-B2 | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | ABBOTT LABORATORIES (US) | 2008-12-09 | — | — | US | disclosed |
| EP-1966157-A2 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS | Abbott Laboratories (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070270476-A1 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS | ABBVIE INC. | 2007-11-22 | — | — | US | disclosed |
| WO-2007059230-A2 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070112047-A1 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS | ABBVIE INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070037807-A1 | Pyridine compounds as inhibitors of dipeptidyl peptidase IV | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | US | disclosed |
| EP-1678138-A1 | PYRIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | Takeda Pharmaceutical Company Limited (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042488-A1 | PYRIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112047-A1 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS | PARP1, PARP2, PARP4 | NPC1 2232/4885RAB9A 3905/4885MAPT 2947/4885 |
| US-20070037807-A1 | Pyridine compounds as inhibitors of dipeptidyl peptidase IV | DPP4, DPP3, PEPD | NPC1 2548/4885RAB9A 4731/4885MAPT 4676/4885 |
| US-20070270476-A1 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS | PARP1, PARP2, PARP4 | NPC1 2232/4885RAB9A 3905/4885MAPT 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.